Navigation Links
Labopharm Reports Results for Third Quarter Fiscal 2007
Date:11/9/2007

esult of higher volumes due to shipments of once-daily tramadol to a larger number of markets in the first nine months of fiscal 2007 compared to the first nine months of fiscal 2006.

Gross margin for the first nine months of fiscal 2007, excluding the provision for once-daily tramadol pre-launch inventory and related deposits to manufacturers taken in the second quarter following the delay in the anticipated U.S. launch of once-daily tramadol, net of the non-recurring favourable adjustment discussed for the quarter, increased to 50% from 44% for the first nine months of fiscal 2006. The increase in adjusted gross margin for the first nine months of 2007 was due to higher average selling prices, primarily attributable to the Canadian launch of once-daily tramadol and lower manufacturing costs, which were partially offset by a royalty expense payable to an affiliate of Purdue Pharma to avoid any potential conflict with respect to patents.

Licensing revenue for the first nine months of fiscal 2007 was $4.8 million, and represented a portion of licensing payments received from the Company's licensing and distribution partners for once-daily tramadol. Licensing revenue for the first nine months of fiscal 2006 was $6.8 million. The decrease in licensing revenues was the result of the extensions of the estimated term over which the Company is recognizing the US$20 million up- front payment previously received from Purdue Pharma.

Research and development expenses before research and development tax credits for the first nine months of fiscal 2007 increased to $19.5 million from $14.3 million for the first nine months of fiscal 2006. The increase was primarily due to the Phase III clinical trial for once-daily trazodone that was initiated in the second quarter of fiscal 2007, several pharmacokinetic studies for additional development programs and the general increase in the Company's research and development activities. Research and development tax credits
'/>"/>

SOURCE Labopharm Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
8. Haemacure Reports Third Quarter 2007 Results
9. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
10. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
11. MDS Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...wswire/ -- Album Creative Studios, Inc., a full-se... offering big brand marketing for small businesses...d agency process and services, and tailored them t... says Matt Parker, Creative Director. Album Crea...oven brand-building techniques to build "Rockstar ...
(Date:11/21/2008)...rk together to stop abusive behavior, experts say ...Behavior that was once dismissed as "kids being ki...nting research shows the negative effects on both ...als, schools, parents and even kids themselves are...g behavior. , "Bullying shouldn,t be considere...
(Date:11/21/2008)...tate University College of Medicine research team ...ew layer of regulation in the cell division cycle,...e way cancer begins. , Wang, an assistant profes...ine, said the findings will lead to an improved ab...ign of new drugs that kill cancer cells by inhibit...
(Date:11/21/2008)...-USNewswire/ -- During a memorial service in the ... remembered Lieutenant Governor Catherine Baker Kn... public service, and a tireless advocate for the p...man elected lieutenant governor, Catherine was a n...ndell. "Her family and her faith were driving forc...
Breaking Medicine News(10 mins):Health News:Album Creative Studios Tailors Big Brand Marketing For Small Businesses 2Health News:Getting Tough on Bullying 2Health News:Getting Tough on Bullying 3Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 2Health News:Pennsylvania Governor Rendell Remembers, Celebrates the Life of Lt. Governor Catherine Baker Knoll During Capitol Tribute 3
...An elusive neurotransmitter pathway in the skin ma...rchers, a discovery that, if confirmed, //would be...egulation occurs. In other words, they may have fo...at allows people to release body heat and stay coo...
...UT Southwestern Medical Center is participating in...ed combinations of vitamins, minerals and fish oil...from age-related macular degeneration. “This study...that may influence the development and progression...
...One side says everyone needs to cut back on salt t...niversal salt reduction would be a needless// depr...sn’t a simple answer. In the most general terms, g...mponent of salt) in the diet lowers blood pressure...
...In the 1950s and 1960s, tall girls were coming up ...ctive to marriage suitors than shorter girls//, ma...n treatment to stunt their growth. While estrogen ...its use to conform a child’s height to fit social ...
Other Medicine News:Health News:Substance P May Pre-empt VIP in Regulating Temperature 2Health News:Substance P May Pre-empt VIP in Regulating Temperature 3Health News:New Nationwide Study on Leading Cause of Vision Loss for Seniors 2Health News:Using Hormone Therapy to Shape Children’s Height to Social Norm 2Health News:Using Hormone Therapy to Shape Children’s Height to Social Norm 3
(Date:11/20/2008)...., Nov. 20 Radius Health ("Radius"... $15 million to its second institutional financing...2.5 million and the total amount raised since the ...g institutional investors participated in the fina...cluding MPM Capital, The Wellcome Trust, HealthCar...
(Date:11/19/2008)...Calif., Nov. 19 Amgen,(...gy Company, a subsidiary of,Takeda Pharmaceutical...,enrollment in the Phase 3 MONET1 trial evaluatin...xel and carboplatin for the first-line treatment o... been temporarily suspended,following a planned s...
(Date:11/19/2008)...llion Payment from Roche- , , MONTVALE, N.J...ceuticals Corp. (Nasdaq: MEMY ) today announced ...hase 2 trial of R3487/MEM 3454, its lead alpha-7 n... associated with schizophrenia (CIAS). The Compan..., triggering a $5.0 million payment from its partn...
(Date:11/18/2008)...ssociation,s 2008 Faces of Influenza survey unders...against influenza; Mother and Gold Medalist Kristi..., Nov. 18 While 78 percent of moth...re and potentially life-threatening disease that c... families will get vaccinated this season, accordi...
Breaking Medicine Technology:Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 2Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 3Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 4Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 5Video: New Survey Finds Mothers See Influenza as a Serious Health Threat, but Often Don't Get Their Families Vaccinated 6InkSure and AuthentiForm Announce Assignment of Patent Portfolio 10261 1InkSure and AuthentiForm Announce Assignment of Patent Portfolio 10261 2InkSure and AuthentiForm Announce Assignment of Patent Portfolio 10261 3ActivBiotics Completes Sale of Fixed Assets 3B Expands Due Diligence Initiative for the Sale of Intellectual Property Including Drug Product Candidat 2778 1BioMarin Appoints Dr Gordon Vehar Vice President of Research 2777 1BioMarin Appoints Dr Gordon Vehar Vice President of Research 2777 2BioMarin Appoints Dr Gordon Vehar Vice President of Research 2777 3Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer 2776 1Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer 2776 2Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer 2776 3
...ESS WIRE)--May 8, 2007 - AVANIR,Pharmaceuticals (N...efficacy, safety and improvements in patient-cente...neuropathic (DPN) pain treated,with the investigat...e) will be presented in two scientific posters at ...ain, being held in,Berlin, Germany on June 7 to 10...
...RE)--May 9, 2007 - Results of a Phase 2a,clinical ...d,amikacin) to treat hospital acquired gram-negati...erican Thoracic Society (ATS),International Confer... Dr. Michael S. Niederman, MD, Chairman, Depar...Hospital, Professor of, Medicine; Vice C...
Other Medicine Technology:AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 4Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 2Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 3
Kaye Skin Hook, Single Prong
Designated most popular model or size.
Large deep curve.
Needle tip electrode, davol advantage electrosurgical attachments, 33cm (with extendible outer sheath), non-sterile. These products are supplied non-sterile and must be sterilized before use. Reusabl
Medicine Products: